secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001104659-26-002494
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BCLI issues three convertible notes to institutional investors, total ~$329K principal
--------------------------------------------------------------------------------

- Vanquish Funding: $94.3K note (12% OID), convertible at 65% of lowest trading price upon default, matures Oct 2026.
- Quick Capital: $94.9K note (10% OID), convertible at 75% of lowest trading price upon default, matures Jan 2027.
- Auctus Fund: $140K note (12% OID), convertible at 65% of lowest trading price after 6 months or upon default, matures 12 months.
- Notes include default penalties of 150% of outstanding, cross-default provisions, and beneficial ownership limitations at 4.99%.
- Proceeds used for general working capital; issuance exempt under Section 4(a)(2) and Rule 506.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/0001104659-26-002494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465926002494/tm262523d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer